ALIROCUMAB EFFICACY AND SAFETY IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND WITH OR WITHOUT CLINICAL ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: POOLED ANALYSIS OF 10 ODYSSEY RANDOMIZED TRIALS

Peter H. Jones,Seth Martin,Harold Bays, G.B. John Mancini,Maurizio Averna,Andrei C. Sposito,Michael Koren,Rita Samuel,Alexia Letierce,Marie Baccara-Dinet,R. Scott Wright

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY（2017）

引用 0|浏览8

暂无评分

摘要

Background: The alirocumab (ALI) ODYSSEY clinical trial program recruited patients with hypercholesterolemia, ∼70% of whom had atherosclerotic cardiovascular disease (ASCVD) and were at very high ASCVD risk. This analysis evaluated the lipid-lowering efficacy and safety of ALI among patients with

查看译文

关键词

hypercholesterolemia,clinical atherosclerotic cardiovascular disease,cardiovascular disease

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要